Navigation Links
Lung Cancer Patients Get Blamed for Their Disease
Date:11/14/2008

ung cancer. Fifty-four percent of these patients said they felt there was a stigma attached to the disease. Thirty-one percent felt that strangers or acquaintances had said or done things that showed they blamed the patient for their cancer, and 13 percent said that even members of their treatment team had done so.

Lung cancer continues to be a major public health threat. About 150,000 Americans are hospitalized with the disease each year, according to the U.S. Agency for Healthcare Research and Quality (AHRQ).

"What seems to be happening is that that there is a reduction in incidence, but the number of hospitalizations is holding fairly steady," said Anne Elixhauser, a senior research scientist at the AHRQ. "Patients may be living longer and may be admitted to the hospital more often, or they are getting more aggressive treatment that requires admission to the hospital."

The average hospital stay cost for lung cancer in 2006 cost $14,200, and the death rate was 13 percent, five times higher than the death rate for all hospitalized people.

However, a "blame the victim" mentality is helping to stymie efforts toward early detection and better treatment, the experts said.

"We need earlier disease detection," she said. "We need to understand at a molecular or genetic level what triggers lung cancer in people so it can be detected earlier. We need more treatment options for the earlier stages of the disease, when we have a chance for better outcomes."

Today, 70 percent of lung cancer cases are diagnosed at an advanced stage, Ambrose said, "which is why the survival rate has remained low for decades. Just as has happened in breast cancer, prostate cancer and colon cancer, a robust research pipeline can lead to a significant increase in survival."

But the situation is bleak: One survey of oncologists found nearly two-thirds saying they did not have adequate treatment options for people with advanced lun
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

1

GOOD

Page: 1 2 3

Related medicine news :

1. Saturated Fats Linked to Cancer of Small Intestine
2. Lung Cancer Alliance-California Issues Inaugural State-Specific Report Card on Lung Cancer
3. Fourth Annual EagleBank Foundation Fight Breast Cancer Golf Classic Raises Over $100,000
4. Cancer researcher receives $3.8 million award from US Department of Defense
5. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
6. Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer
7. Lung Cancer May Be Deadlier for Men
8. Cancer treatment may result in bone loss
9. American Academy of Dermatology: Stop Skin Cancer On The Spot
10. Gender is key factor in determining overall survival of lung cancer patients
11. Proton therapy may reduce serious side effect of lung cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lung Cancer Patients Get Blamed for Their Disease
Lung Cancer Patients Get Blamed for Their Disease
Breaking Medicine News(10 mins):Health News:Study highlights implications of influenza pandemics on blood supplies 2Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 2Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 3Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 4Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 2Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 3Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 4Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 2Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 3Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 4
Breaking Medicine Technology:Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 2Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 3Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 4Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 5Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 8Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 9Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 10Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 1Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 2Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 3Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 4Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 1Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 2Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 3Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 4Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 1Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 2Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 3
Other Medicine Technology:Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 2Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 3Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 4Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 5Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 2Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 3Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 4Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 5Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 6Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 7